Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
943.4 USD | -0.75% |
|
+1.29% | +62.04% |
02:35pm | Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793 | MT |
09:00am | Novo owner backs Swiss biotech Asceneuron in $100 million round | RE |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.04% | 856B | |
+38.95% | 631B | |
-4.06% | 359B | |
+15.35% | 325B | |
+9.05% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.94% | 177B | |
+2.26% | 165B | |
+2.41% | 126B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Transcript : Eli Lilly and Company, Q4 2020 Earnings Call, Jan 29, 2021